CRISPR Therapeutics (NASDAQ: CRSP) GC sells shares for tax withholding

Rhea-AI Filing Summary

CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported RSU vesting and a related share sale. On March 14, 2026, 6,875 restricted stock units converted into 6,875 common shares at $0.00 per share, as part of a 27,500-share RSU grant vesting annually from 2026 to 2029.

On March 16, 2026, he sold 3,450 common shares at $48.26 per share to cover tax withholding obligations under the company’s RSU Settlement Policy, which the footnote states was not a discretionary trade. After these transactions, he directly holds 91,240 common shares and 20,625 restricted stock units, with remaining shares subject to a lock-up agreement tied to the company’s convertible senior notes due 2031.

Insider Trade Summary

Net Seller: 3,450 shares ($166,497)

Net Sell 3 txns

Insider KASINGER JAMES R.

Role General Counsel and Secretary

Sold 3,450 shs ($166K)

Type	Security	Shares	Price	Value
Sale	Common Shares	3,450	$48.26	$166K
Exercise	Restricted Stock Units	6,875	$0.00	--
Exercise	Common Shares	6,875	$0.00	--

Holdings After Transaction: Common Shares — 91,240 shares (Direct); Restricted Stock Units — 20,625 shares (Direct)

Footnotes (1)

1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KASINGER JAMES R.

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MA 02127

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/14/2026		M(1)		6,875	A	(2)	94,690	D
Common Shares	03/16/2026		S		3,450(3)	D	$48.26	91,240	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/14/2026		M(1)			6,875	(4)	(4)	Common Shares	6,875	(2)	20,625	D

Explanation of Responses:

1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

3. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

4. This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.

	Elizabeth Ryland Waldinger, attorney-in-fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CRSP executive James R. Kasinger report on this Form 4?

James R. Kasinger reported RSU vesting and a related sale. 6,875 restricted stock units converted into common shares on March 14, 2026, followed by a March 16, 2026 sale of 3,450 common shares at $48.26 per share to satisfy tax obligations.

How many CRISPR Therapeutics (CRSP) shares did Kasinger sell and at what price?

Kasinger sold 3,450 CRISPR Therapeutics common shares at $48.26 per share. According to the footnote, this transaction was executed to cover tax withholding obligations related to RSU vesting and was mandated by the company’s RSU Settlement Policy, not a discretionary trade.

Was the CRSP insider share sale by James R. Kasinger a discretionary transaction?

The filing states the sale was not discretionary. It explains the 3,450 shares sold on March 16, 2026 were required to cover tax withholding when RSUs vested, pursuant to CRISPR Therapeutics’ RSU Settlement Policy, rather than being a voluntary open-market trade.

How many CRISPR Therapeutics shares and RSUs does Kasinger hold after these transactions?

After the reported transactions, Kasinger directly holds 91,240 common shares and 20,625 restricted stock units. The filing also notes that these shares remain subject to a lock-up agreement associated with CRISPR Therapeutics’ offering of convertible senior notes due 2031.

What is the vesting schedule for James R. Kasinger’s CRSP restricted stock unit award?

The RSU award was granted March 14, 2025 for 27,500 common shares. One quarter vests on March 14, 2026, another quarter on March 14, 2027, another on March 14, 2028, and the final quarter on March 14, 2029, creating four equal annual vesting events.

How were Kasinger’s RSUs converted into CRISPR Therapeutics common shares?

Each restricted stock unit represents a contingent right to receive one common share. On March 14, 2026, 6,875 RSUs vested and were converted into 6,875 common shares at a conversion price of $0.00 per share, as part of his 27,500-share RSU grant.